Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25065372 | 0.84 | EGFR (0.43) | EGFRPDGFRBPDGFRAPIK3CDPIK3CA | |
| SCHEMBL27918893 | 0.84 | EGFR (0.52) | EGFRPDGFRBPDGFRAPIK3CDPIK3CA | |
| SCHEMBL31753984 | 0.84 | EGFR (0.43) | EGFRPDGFRBPDGFRAPIK3CDPIK3CA | |
| SCHEMBL24924336 | 0.84 | EGFR (0.44) | EGFRPDGFRBPDGFRAPIK3CDPIK3CA | |
| SCHEMBL3892773 | 0.84 | EGFR (0.43) | EGFRPDGFRBPDGFRAPIK3CDPIK3CA | |
| SCHEMBL8874014 | 0.83 | EGFR (0.58) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| Hydroquinone SCHEMBL8878778 | 0.80 | EGFR (0.52) | EGFRPDGFRBPDGFRAPIK3CDPIK3CA | |
| SCHEMBL25065174 | 0.79 | EGFR (0.40) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL4593258 | 0.79 | EGFR (0.51) | EGFRPDGFRBPDGFRAFGFR4 | |
| SCHEMBL24253515 | 0.79 | EGFR (0.40) | EGFRPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121429-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | 아주대학교산학협력단 | 2023-06-29 | — | — | WO | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| US-8173806-B2 | Method for production of quinazolin-4-one derivative | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-1997812-B1 | METHOD FOR PRODUCTION OF QUINAZOLIN-4-ON DERIVATIVE | MITSUBISHI GAS CHEMICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20090054646-A1 | Method for Production of Quinazolin 4-One Derivative | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1997812-A1 | METHOD FOR PRODUCTION OF QUINAZOLIN-4-ON DERIVATIVE | Mitsubishi Gas Chemical Company, Inc. (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-7078409-B2 | Fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2003082830-A1 | NOVEL FUSED QUINAZOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | BETA PHARMA, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | ABL1, ERBB2, CNKSR1 | EGFR 82/4885PDGFRB 897/4885PDGFRA 616/4885 |
| US-20090054646-A1 | Method for Production of Quinazolin 4-One Derivative | NQO2, ALDH7A1, ALAD | EGFR 3629/4885PDGFRB 3861/4885PDGFRA 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.